Osteologix Inc. is a specialty biopharmaceutical company committed to improving the health of those afflicted with musculoskeletal diseases, such as osteoporosis. Their lead product candidate, NB S101, is a dual-acting bone agent for the treatment of osteoporosis. Osteologix trades on the OTCBB as part of the Diagnostic Substances industry. Their headquarters are in Glen Allen, Virginia.

The company’s commitment is to developing innovative pharmaceuticals for the treatment and prevention of diseases of the bones and joints. Osteologix works to collaborate with others in the healthcare community. These collaborations apply new scientific information and clinical data to the development of products that improve patient care in a safe and ethical manner.

Osteologix is developing NB S101 as a treatment for osteoporosis. It is a once-daily tablet containing strontium malonate. The phase II study evaluating NB S101 is a randomized, double blind, placebo-controlled, parallel-group efficacy and safety trial. Its objective is to assess the effects of NB S101 on bone metabolism. The study also evaluates the product’s safety, tolerability, and pharmacokinetics in postmenopausal women. Osteologix is also evaluating NB S101’s effect on bone formation and bone mineral density.

Osteologix Inc.’s focus is to proceed with NB S101 to late-stage clinical development. They also want to partner with an international pharmaceutical company for the commercialization of the product. Furthermore, they are looking for additional projects for collaboration and partnership in musculoskeletal and metabolic areas.

Let us hear your thoughts below: